Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

124.95 +4.35 (+3.61%)
Streaming Delayed Price Updated: 2:33 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
News headline image
Moderna Stock Looks Ripe for a Short Squeeze
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze 
Via MarketBeat
Topics Government
News headline image
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Via The Motley Fool
Topics Economy Law Enforcement
News headline image
Spotlight on Merck & Co: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals ↗
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector. 
Via Chartmill
News headline image
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Daiichi Sankyo
Via Business Wire
News headline image
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
From Merck & Co., Inc.
Via Business Wire
News headline image
Decoding Merck & Co's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
News headline image
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo ↗
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
News headline image
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 ↗
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
News headline image
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
From Merck & Co., Inc.
Via Business Wire
News headline image
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
News headline image
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up ↗
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
News headline image
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors ↗
Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase. 
Via Benzinga
News headline image
3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows ↗
Via The Motley Fool
Topics Artificial Intelligence World Trade
News headline image
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
News headline image
Assessing Merck & Co: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Top S&P500 movers in Tuesday's session ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
From Merck & Co., Inc.
Via Business Wire
News headline image
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN) ↗
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
News headline image
Dow Jones Adds 1,000 Points, Breaks 200-Day Moving Average For First Time Since April 2 Tariff Shock ↗
The Dow surged 1,100 points after a U.S.-China trade truce, breaking above its 200-day average and fueling hopes of a market rebound — with caveats. 
Via Benzinga
Topics Stocks
News headline image
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order ↗
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries. 
Via Stocktwits
Topics Government
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
News headline image
MRK Q1 Earnings Call: Pipeline Expansion, Tariff Pressures, and Portfolio Diversification
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $15.53 billion. The company expects the... 
Via StockStory
Topics Economy World Trade
News headline image
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.